Navigation Links
Understanding Managed Markets: Effective Market Research Structures & Activities to Maximize Payer Access & Insights
Date:7/20/2009

CHAPEL HILL, N.C., July 20 /PRNewswire/ -- Today's physicians are losing influence over patients' drug utilization decisions. Now, a large number of bio-pharmaceutical companies control the vast majority of prescription drug expenditures. Continued formulary access depends largely on a company's ability to evolve its MMMR (Managed Markets Market Research) structures to work effectively in the current payer-driven environment.

Best Practices, LLC initiated research to assist leaders of Market Research and Managed Markets in identifying tactics and success factors for understanding and acting upon the needs of third-party payers. A well-structured MMMR group facilitates a relationship between bio-pharma and third-party payers that offers competitive advantage to both parties.

Sample key findings that emerged from this research are the following:

  • Don't Wait Until It's Too Late to Develop MM Insights: MMMR activities peak during Phase 3, though most benchmark partners are moving to push these into earlier phases. This may prove most viable for breakthrough medicines where pharmacoeconomic differences can be identified, and may prove less effective for me-too drugs, as pushing research earlier may give payers more time to develop strategies against undifferentiated products.
  • Performance Guarantees/Warranties: Eighty percent of benchmarked companies have explored the concept of offering warranties, but most find their usefulness limited due to unpredictable patient compliance and complex Medicaid-related CMS submissions. The warranty concept seems best applied for novel drugs in unique therapeutic categories where Medicaid is not a major payer.

This report is based on an analysis of survey results and interview content collected from 11 participating companies including Abbott Labs, Alcon, Amgen, GlaxoSmithKline, Jazz Pharmaceuticals, Johnson & Johnson, Novo Nordisk, Sepracor, Solvay, Ther-Rx and Xanodyne Pharmaceuticals.

A Report excerpt, "Understanding Managed Markets: Effective Market Research Structures & Activities to Maximize Payer Access & Insights", is available at http://www3.best-in-class.com/ or copy and paste the following URL in your browser http://www3.best-in-class.com/rr983.htm

For more information, on Best Practices, LLC's research and services, contact Cameron Tew, Executive Director at Best Practices, LLC at (919) 767-9246 or ctew@best-in-class.com.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for nearly 15 years; our clients include 43 out of the top 50 pharmaceutical companies.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Campaign to Increase the Awareness and Understanding of Lou Gehrigs Disease Reaches 22 U.S. States
2. New Survey Reveals Gap in Understanding of Alzheimers Disease Risk and Prevention Among Most Vulnerable Populations
3. Immtech and Beijing Pharmaceutical Group Co. Sign Memorandum of Understanding to Explore Developing Strategic Business Alliance
4. Understanding the science of solar-based energy: more researchers are better than one
5. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
6. Scientists fix bugs in our understanding of evolution
7. Digirad Corporation Signs Letter of Understanding With Johns Hopkins University School of Medicine
8. March of Dimes Awards $250,000 Prize to Leaders in Understanding Embryonic Development
9. Understanding of actuator properties of carbon nanotubes bring micro machines closer
10. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
11. URAC Director of Pharmacy Programs to Speak at Academy of Managed Care Pharmacy Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - http://photos.prnewswire.com/prnh/20160524/371420 ... ... ... With ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
Breaking Biology News(10 mins):